Biosimilars Forum Welcomes PBM Transparency Act

US Proposals Would See Spread Pricing Outlawed And Rebates Disclosed

Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.

Man writing the word transparency
The proposals would require significantly increased transparency from PBMs. • Source: Shutterstock

The Biosimilars Forum has welcomed a piece of bipartisan legislation introduced by US senators Maria Cantwell and Chuck Grassley, which would crack down on certain pharmacy benefit manager business practices that the Forum believes have a negative impact on the biosimilars industry.

More from Policy & Regulation

More from Generics Bulletin